GCS-100 Technology

GCS-100 is a complex polysaccharide that has the ability to bind to and block the effects of galectin-3.  The unique ability of GCS-100, to bind and sequester galectin-3 makes it an ideal candidate to prevent and treat diseases in which galectin-3 plays an important role, such as chronic organ failure and cancer.

GCS-100 is a complex, naturally occuring polysaccharide derived from pectin that has the ability to bind to and block the effects of galectin-3. A description of GCS-100 can be found here. GCS-100 is composed of several types of sugars arranged in a complex polymeric configuration with multiple side-branches. In particular GCS-100 has multiple side-branches containing the sugar β-galactose which is recognized by galectin-3’s carbohydrate binding domain. Thus GCS-100 is able to bind to and sequester multiple molecules of extracellular (circulating) galectin-3.

The unique ability of GCS-100, to bind and sequester galectin-3 makes it an ideal candidate to prevent and treat diseases in which galectin-3 plays an important role, such as chronic organ failure and cancer. Additionally, because of its high average molecular weight (~1000 kD), GCS-100 resides in the body for an extended period, increasing the time to interact with and sequester circulating galecin-3.

How GCS-100 Works

gsc100-fig1

General Structure of GCS-100

GCS-100 is a derivative of pectin, a naturally occurring polysaccharide found in the structure of various plants including the pulp and peel of citrus fruits. Pectin is composed of several types of sugars arranged in a complex polymeric configuration with multiple side-branches. In particular pectins have multiple side-branches containing the sugar β-galactose which is recognized by galectin-3’s carbohydrate binding domain. Thus GCS-100 is able to bind to and sequester multiple molecules of extracellular (circulating) galectin-3.

Additionally, because of its high average molecular weight (~1000 kD), GCS-100 resides in the body for an extended period, increasing the time to interact with and sequester circulating galecin-3.

gsc100-fig2

Galectin-3 Bound to GCS-100

To date, GCS-100 has been tested in nine phase 1 and 2 clinical trials involving greater than 140 human subjects. Data from these and preclinical studies have shown:

  • The product is well tolerated with no significant impact on normal cells.
  • Initial signals of single agent activity in patients with solid and hematological tumors.
  • Additive and synergistic efficacy in combination therapy with no overlapping toxicities.

Publications on the use of GCS-100 can be found here.